Wed, May 9, 2012
Tue, May 8, 2012
Mon, May 7, 2012
Sat, May 5, 2012
Fri, May 4, 2012
Thu, May 3, 2012
[ Thu, May 03rd 2012 ] - Market Wire
00 p.m. EDT
Wed, May 2, 2012
[ Wed, May 02nd 2012 ] - Market Wire
Location Change
Tue, May 1, 2012
Mon, April 30, 2012
[ Mon, Apr 30th 2012 ] - Market Wire
Hologic to Acquire Gen-Probe
Sun, April 29, 2012
Sat, April 28, 2012
Fri, April 27, 2012
Thu, April 26, 2012
Wed, April 25, 2012
Tue, April 24, 2012

Orexigen Therapeutics Schedules May 9, 2012 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2012


//health-fitness.news-articles.net/content/2012/ .. s-for-the-first-quarter-ended-march-31-2012.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Orexigen Therapeutics Schedules May 9, 2012 Webcast Discussion of Financial Results for... -- SAN DIEGO, May 1, 2012 /PRNewswire/ --

Orexigen Therapeutics Schedules May 9, 2012 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2012

[ ]

SAN DIEGO, May 1, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: [ OREX ]), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the first quarter ended March 31, 2012 on Wednesday, May 9, 2012 after the markets close. The announcement will be followed by a live webcast and conference call at 5 p.m. Eastern time (2 p.m. Pacific time).

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (866) 277-1184 (domestic) or (617) 597-5360 (international), participant code 94351243. The webcast can be accessed live on the investor relations section of the Orexigen web site at [ www.orexigen.com ] and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials for which a New Drug Application has been submitted and reviewed by the FDA, and the FDA has agreed to a SPA for the Contrave outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at [ www.orexigen.com ].

 

McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600

 

SOURCE Orexigen Therapeutics, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.orexcigen.com ]


Publication Contributing Sources